Traditional cancer therapeutics, such as chemotherapies, are often limited by their non-
specific nature, causing harm to non-malignant tissues. Over the past several decades …

Cancer immunology and immunotherapy are driving forces of research and development in
oncology, mostly focusing on CD8+ T cells and the tumor microenvironment. Recent …

Therapeutic cancer vaccines have undergone a resurgence in the past decade. A better
understanding of the breadth of tumour-associated antigens, the native immune response …

Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has greatly improved
the clinical efficacy of malignant tumor therapy. ICI-mediated antitumor responses depend …

Cancer vaccines based on resected tumors from patients have gained great interest as an
individualized cancer treatment strategy. However, eliciting a robust therapeutic effect with …

Cancer immunotherapy aims to promote the activity of cytotoxic T lymphocytes (CTLs) within
a tumour, assist the priming of tumour-specific CTLs in lymphoid organs and establish …

Recent advances in several areas are rekindling interest and enabling progress in the
development of therapeutic cancer vaccines. These advances have been made in target …

The recent success of immunotherapies has highlighted the power of leveraging the
immune system in the fight against cancer. In order for most immune‐based therapies to …

Immunotherapy strategies that use cell‐based delivery systems have sparked much interest
in the treatment of malignancies, owing to their high biocompatibility, excellent tumor …

Here we present a protocol for the construction and use of two types of nanocarrier based on
bacterial membrane materials for cancer vaccine delivery. Cancer vaccines induce tumor …